EN
BLOG

NEWSROOM

Reference countries used in drug pricing in Turkey have been announced
Reference countries used in drug pricing in Turkey have been announced
31.08.2023
HEALTH/SPORTS

While drug prices in Turkey continue to be updated according to exchange rate changes, a new drug market research has been added. In the Detailed Drug List Analysis of 2022 published by ECONiX Research, the current table on the pricing of drugs was revealed, and the shares of the reference countries were also announced.

TURKEY — While the health sector has also been affected recently when global economic fluctuations have gained momentum, pharmaceutical prices continue to be updated according to exchange rate changes in our country and the world. ECONiX Research, aiming to evaluate the changes in Turkey's pharmaceutical market, has published the Detailed Drug List Analysis for 2022, in which it examined 8,698 drugs on the active products list as of December 2022. In the report, while explaining the countries that are taken as a reference in determining drug prices in Turkey, he also conveyed the sales prices of drugs to warehouses on a global scale.

Generic drugs accounted for 69% of drugs

Expert Ekin Begüm Karahan from the ECONiX Research team and one of the researchers of the report, who stated that the drugs examined in the list of active products within the scope of the research were based on two different criteria, said, “The reference country system has been used in the determination of drug prices in Turkey since 2004. In this system, the lowest price is taken as a basis by comparing the drug prices of at least 5 and at most 10 European Union (EU) countries determined by the Ministry of Health of the Republic of Turkey. We have two categories in the drugs we examine in our report, such as original and generic products.”

In the Detailed Drug List Analysis of 2022, 2 706 original and 5 992 generic drugs were examined. Apart from the original and generic status of the drugs, the sales prices to the warehouse and the sectoral map of the reference regions were other important factors analyzed.

There is no prominent country in drug pricing

According to the results of the analysis shared by ECONiX, the average sales price of the original drugs to the warehouse was determined as 4 thousand 265 Turkish liras, while the average sales price of the generic drugs to the warehouse was 586 Turkish liras. From the ECONiX Research team and one of the report's researchers, Phar. Yaren Erkut “There is no single country's superiority in pricing Turkey's original drugs.” used the phrases. In the report, it was noted that while it was noted that drugs in Turkey took Greece as a reference with a rate of 21%, it was followed by France with 16%, Italy and Spain with 12%. A similar picture was seen in the pricing of generic drugs. On the other hand, it has been demonstrated that countries such as Germany and Switzerland, which are not among the official reference countries, play an essential role in drug pricing. Globally, Switzerland ranked first with the highest average price in the sale of both original and generic drugs to the warehouse, while Portugal was positioned as the country with the lowest average price.

ECONiX Research Management Team Dr. Güvenç Koçkaya said, “The Detailed Drug List, which is prepared and published by the Turkish Medicines and Medical Devices Agency within the scope of the relevant legislation, is updated every year for reasons such as the inclusion and removal of drugs from the list, reference country and price changes, and fixed exchange rates. Regular changes are made in the list, which is published every Friday, at the end of the day. As ECONiX Research, we follow the weekly and daily changes. Thus, while evaluating the changes in the Turkish pharmaceutical market, we offer important outputs to the authorities and sector stakeholders. Apart from areas such as medical supplies, health service providers, market access, health economics, medical and business development, we prepare reports that will adopt the market approaches of the sector stakeholders and shed light on the health economy with our research, analysis and consultancy services. We hope that the Detailed Drug List Analysis for 2022 will also be useful.” used the phrases.

Contact: Tülay Genç | [email protected] | +31 30 799 6022

You can use the press releases published by B2Press in your media for free.
Fill the form immediately, get all the news instantly.
PUBLISHER REQUEST FORM
Please enter a valid name.
Please enter a valid e-mail address.
Please approve.
© B2Press B.V.
B2Press
Sending...
B2Press